The cost of entry: An analysis of pharmaceutical registration fees in low-, middle-, and high-income countries.

We find that, generally speaking, the regulatory fees charged by medicines regulatory authorities are roughly proportional to the market size in their jurisdictions. The data therefore do not support the hypothesis that regulatory fees are a barrier to market entry in most countries.